Lanzhou, China

Xingnian Fu

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 13.2

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Lanzhou, CN (2013)
  • Gansu Province, CN (2013)
  • Shanghai, CN (2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xingnian Fu

Introduction

Xingnian Fu is a prominent inventor based in Lanzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target PRC2-mediated diseases. With a total of five patents to his name, Fu's work is recognized for its potential therapeutic applications.

Latest Patents

Among his latest patents are two notable inventions. The first is related to triazolopyridine compounds, which are described as a compound of Formula (IA) or a pharmaceutically acceptable salt thereof. This compound has been shown to be useful for treating a PRC2-mediated disease or disorder. The second patent focuses on imidazolepyridine compounds, also described as a compound of Formula (IA) or a pharmaceutically acceptable salt thereof, which similarly demonstrates utility in treating PRC2-mediated diseases or disorders.

Career Highlights

Xingnian Fu is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development efforts in innovative pharmaceutical solutions. Fu's expertise in medicinal chemistry has positioned him as a valuable asset in the industry.

Collaborations

Fu collaborates with several talented individuals in his field, including Yuan Mi and Zhengtian Yu. These collaborations enhance the research environment and contribute to the advancement of their collective work in pharmaceutical innovations.

Conclusion

Xingnian Fu's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a key inventor. His work continues to pave the way for new treatments that address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…